Abstract
Type 1 diabetes (T1D) is an autoimmune disease, leading to pancreatic β-cell destruction and loss of glycaemic control. Administration of exogenous insulin to diabetic patients prevents life-threatening metabolic derangement, but may fail to prevent other longterm complications, such as kidney failure or diabetic retinopathy. Islet transplantation is a low-risk surgical procedure, affording improved glucose homeostasis provided sufficient islets engraft in the liver. Here we review work on the use of stem cells to generate β- cells for islet transplantation, indicating the need for improved protocols for their derivation and full maturation. We also consider recent evidence indicating that adult stem/progenitor cells may affect islet transplantation by improving the viability of engrafted islets and controlling immune reactions to islet allo- and auto-antigens, extending stem-cell use in T1D beyond the regenerative approach.
Keywords: Pancreatic islet, transplantation, autoimmunity, mesenchymal stem cells, regeneration, graft rejection, Calcium, insulin resistance, diabetes, vascular endothelial growth factor (VEGF)
Current Pharmaceutical Design
Title: Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach
Volume: 17 Issue: 29
Author(s): Biancamaria Longoni and Franco Mosca
Affiliation:
Keywords: Pancreatic islet, transplantation, autoimmunity, mesenchymal stem cells, regeneration, graft rejection, Calcium, insulin resistance, diabetes, vascular endothelial growth factor (VEGF)
Abstract: Type 1 diabetes (T1D) is an autoimmune disease, leading to pancreatic β-cell destruction and loss of glycaemic control. Administration of exogenous insulin to diabetic patients prevents life-threatening metabolic derangement, but may fail to prevent other longterm complications, such as kidney failure or diabetic retinopathy. Islet transplantation is a low-risk surgical procedure, affording improved glucose homeostasis provided sufficient islets engraft in the liver. Here we review work on the use of stem cells to generate β- cells for islet transplantation, indicating the need for improved protocols for their derivation and full maturation. We also consider recent evidence indicating that adult stem/progenitor cells may affect islet transplantation by improving the viability of engrafted islets and controlling immune reactions to islet allo- and auto-antigens, extending stem-cell use in T1D beyond the regenerative approach.
Export Options
About this article
Cite this article as:
Longoni Biancamaria and Mosca Franco, Stem Cell-Based Immunomodulation in Type 1 Diabetes: Beyond the Regenerative Approach, Current Pharmaceutical Design 2011; 17 (29) . https://dx.doi.org/10.2174/138161211798157595
DOI https://dx.doi.org/10.2174/138161211798157595 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?
Current Vascular Pharmacology Editorial: Cocaine and Cerebral Small Vessel: Is it a Negative Factor for Intravenous Thrombolysis?
Current Vascular Pharmacology Autoantibodies for Cardiac Channels and Sudden Cardiac Death and its Relationship to Autoimmune Disorders
Current Cardiology Reviews Role of Differential Signaling Pathways and Oxidative Stress in Diabetic Cardiomyopathy
Current Cardiology Reviews Progression of Renal Dysfunction in Patients with Cardiovascular Disease
Current Cardiology Reviews Application of Resveratrol in Diabetes: Rationale, Strategies and Challenges
Current Molecular Medicine The Emerging Roles of Leptin and Ghrelin in Cardiovascular Physiology and Pathophysiology
Current Vascular Pharmacology Role of Carbon Monoxide in Vascular Diseases
Current Pharmaceutical Biotechnology Antileukotriene Drugs: Clinical Application, Effectiveness and Safety
Current Medicinal Chemistry Heme Oxygenase-1 in Vascular Smooth Muscle Cells Counteracts Cardiovascular Damage Induced by Angiotensin II
Current Neurovascular Research ABCC6 as a Target in Pseudoxanthoma Elasticum
Current Drug Targets Regulatory Light Chains of Striated Muscle Myosin. Structure, Function and Malfunction
Current Drug Targets - Cardiovascular & Hematological Disorders Sildenafil and Cardioprotection
Current Pharmaceutical Design Kinin Receptors in Vascular Biology and Pathology
Current Vascular Pharmacology Diagnostic Value of HLA Typing in Pathogenesis of Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets ROS Acts as a Double-Edged Sword in the Pathogenesis of Type 2 Diabetes Mellitus: Is Nrf2 a Potential Target for the Treatment?
Mini-Reviews in Medicinal Chemistry The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry The Role of Heat Shock Protein (HSP) in Atherosclerosis: Pathophysiology and Clinical Opportunities
Current Medicinal Chemistry Chaperones and Cardiac Misfolding Protein Diseases
Current Protein & Peptide Science